Initial Treatment Recommendations for Adults with Colitis

Assessment and Classification

The American Gastroenterological Association (AGA) suggests early use of biologic agents with or without immunomodulator therapy rather than gradual step-up after failure of 5-aminosalicylates 3

For adults diagnosed with colitis, the initial treatment should focus on 5-aminosalicylates (5-ASA) for mild to moderate disease, while moderate to severe disease requires corticosteroids or biologic agents depending on disease severity 1, 2
First-line treatment for mild to moderate disease is oral and rectal 5-aminosalicylates (mesalazine 4g/day) 2
For distal colitis, combination of topical mesalazine and oral mesalazine provides better relief than either alone 2
For patients failing 5-ASA therapy or presenting with moderate-severe disease, oral corticosteroids (prednisolone 40mg daily) are recommended 1, 2
Biologic options include TNF-α antagonists (infliximab, adalimumab, golimumab), vedolizumab, ustekinumab, or JAK inhibitors (tofacitinib, upadacitinib) 1, 4
For biologic-naive patients, infliximab or vedolizumab are preferred over adalimumab for induction of remission 4
JAK inhibitors (tofacitinib) should only be used after failure of TNF-α antagonists per FDA recommendations 4

Intravenous methylprednisolone (dose equivalent of 40-60mg/day) is recommended for severe acute colitis 3
Close monitoring with daily physical examination, vital signs, stool chart, and laboratory tests is essential 2
Joint management by gastroenterologist and colorectal surgeon is recommended 2
For steroid-refractory disease, infliximab or cyclosporine can be used as rescue therapy 3
Subcutaneous heparin can be used to reduce thromboembolism risk 2
Nutritional support is recommended if malnourished 2

For moderate-severe UC, consider combining TNF-α antagonists, vedolizumab, or ustekinumab with thiopurines or methotrexate rather than biologic monotherapy 3
The AGA suggests against using thiopurine monotherapy for induction of remission 1, 3
The AGA suggests against using methotrexate monotherapy for induction or maintenance of remission 3

Lifelong maintenance therapy is generally recommended, especially for patients with left-sided or extensive disease 2
Options include 5-aminosalicylates, azathioprine, or mercaptopurine 2
In patients who achieve remission with biologics and/or immunomodulators, the AGA suggests against continuing 5-aminosalicylates for maintenance 3

Patients should be informed about treatment options and prognosis, including a 25-30% chance of needing colectomy in severe cases 2
Consider early surgical consultation for patients with severe disease not responding to medical therapy 2
Recognize that acute onset UC can be difficult to distinguish from infectious colitis, but treatment with corticosteroids should not be delayed while awaiting stool microbiology results 2